Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
- PMID: 12686805
- DOI: 10.1097/01.ju.0000062674.43964.d0
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy
Abstract
Purpose: In the last decade numerous groups have shown that low levels of pretreatment serum total testosterone consistently predict more aggressive disease, worse prognosis and worse treatment response in patients with metastatic prostate cancer. Prior studies have not demonstrated this same correlation in patients with known localized disease. We rigorously tested pretreatment total testosterone levels as a potential staging and prognostic marker in a large cohort of 879 patients with localized cancer treated with radical prostatectomy.
Materials and methods: We retrospectively reviewed the clinical records of 879 patients treated with radical prostatectomy between January 1, 1986 and June 30, 2002 from 9 hospital sites. Nonparametric tests were used to compare the relationship of pretreatment testosterone to other variables. Multivariate logistic regression analysis was used to assess clinical predictors of extraprostatic disease. Kaplan-Meier survival methods and Cox regression analysis were used to assess predictors of biochemical recurrence.
Results: Patients with non-organ confined prostate cancer (pT3-T4) showed significantly lower pretreatment total testosterone levels than those with organ confined cancer (pT1-T2) (nonparametric p = 0.041). In multivariate analysis pretreatment total testosterone emerged as a significant independent predictor of extraprostatic disease (p = 0.046). Total testosterone was not a significant predictor of biochemical (prostate specific antigen) recurrence (p = 0.467).
Conclusions: Pretreatment total testosterone was an independent predictor of extraprostatic disease in patients with localized prostate cancer. As testosterone decreases patients have an increased likelihood of non-organ confined disease. Low testosterone was not predictive of biochemical recurrence, although trends observed dictate study in larger cohorts with mature followup.
Comment in
-
Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.J Urol. 2003 Dec;170(6 Pt 1):2392; author reply 2392. doi: 10.1097/01.ju.0000095148.84868.ba. J Urol. 2003. PMID: 14634433 No abstract available.
Similar articles
-
Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.Eur Urol. 2005 Mar;47(3):308-12. doi: 10.1016/j.eururo.2004.11.003. Epub 2004 Dec 29. Eur Urol. 2005. PMID: 15716191 Clinical Trial.
-
Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.J Urol. 2007 Oct;178(4 Pt 1):1277-80; discussion 1280-1. doi: 10.1016/j.juro.2007.05.153. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698121
-
Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.J Urol. 2003 Jun;169(6):2136-41. doi: 10.1097/01.ju.0000065588.82511.06. J Urol. 2003. PMID: 12771735
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
-
Prostate cancer risk in testosterone-treated men.J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. doi: 10.1016/j.jsbmb.2006.09.032. J Steroid Biochem Mol Biol. 2006. PMID: 17113983 Review.
Cited by
-
Testosterone deficiency and replacement: Myths and realities.Can Urol Assoc J. 2014 Jul;8(7-8 Suppl 5):S145-7. doi: 10.5489/cuaj.2309. Can Urol Assoc J. 2014. PMID: 25243038 Free PMC article. Review.
-
BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people.Oncotarget. 2017 Aug 2;8(39):66051-66060. doi: 10.18632/oncotarget.19790. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029491 Free PMC article.
-
Prostate size is associated with surgical difficulty but not functional outcome at 1 year after radical prostatectomy.J Urol. 2009 Sep;182(3):949-55. doi: 10.1016/j.juro.2009.05.029. Epub 2009 Jul 17. J Urol. 2009. PMID: 19616260 Free PMC article.
-
More aggressive prostate cancer in elderly men.Rev Urol. 2013;15(4):202-4. Rev Urol. 2013. PMID: 24659918 Free PMC article. Review. No abstract available.
-
Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update.Exp Diabetes Res. 2012;2012:801610. doi: 10.1155/2012/801610. Epub 2012 Jun 26. Exp Diabetes Res. 2012. PMID: 22792092 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials